Literature DB >> 20357529

[Seroprevalence of IgG anti-HAV in hospital employees below 40 years old].

Du Young Noh1, Yong Chan Cho, Won Jung Jun, Sung Kyun Kim, Kyoung Won Yun, Seon Young Park, Wan Sik Lee, Yeong Eun Ju, Hyun Soo Kim, Sung Kyu Choi, Jong Sun Rew.   

Abstract

BACKGROUND/AIMS: Hepatitis A is an acute infectious disease transmitted by fecal-oral route. As the incidence of hepatitis A has been increased in Gwangju and Chonnam province of Korea recently, the number of hepatitis A patients in hospital employees has also increased. Thus, we investigated the seroprevalence of IgG anti-HAV in hospital employees below 40 years old.
METHODS: We analysed the seroprevalence of anti-HAV IgG from 1,002 Chonnam national university hospital employees (men: 190, women: 812) who were below 40 years old. The age group was divided by 5 years; 21-25 years old 199 (19.9%), 26-30 years old 426 (42.5%), 31-35 years old 215 (21.5%), 36-40 years old 162 (16.1%).
RESULTS: Overall seropositive rate of IgG anti-HAV was 32.8% (329/1,002). The seropositive rate of men was 40.5% (77/190) and that of women was 31.0% (252/812). The seropositive rates of each age group were 1.5% (3/199) in 21-25 years old, 21.6% (92/426) in 26-30 years old, 48.4% (104/215) in 31-35 years old, and 80.2% (130/162) in 36-40 years old. The seropositivity rate of the high risk group (doctors, nurses, technicians) was 28.9% (234/809).
CONCLUSIONS: The seropositive rate of IgG anti-HAV was the lowest in early twenties of hospital employees and below 50% in early thirties. Therefore, hepatitis A vaccination may be warranted in the hospital employees below the early thirties.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357529     DOI: 10.4166/kjg.2010.55.3.183

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  1 in total

1.  Seroprevalence and disease burden of acute hepatitis A in adult population in South Korea.

Authors:  Jin Gu Yoon; Min Joo Choi; Jae Won Yoon; Ji Yun Noh; Joon Young Song; Hee Jin Cheong; Woo Joo Kim
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.